{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:15:24Z","timestamp":1740158124019,"version":"3.37.3"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clml.2024.03.005","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T11:28:51Z","timestamp":1711106931000},"page":"350-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-1275","authenticated-orcid":false,"given":"Noopur S.","family":"Raje","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels W.C.J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clml.2024.03.005_bib0001","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment","volume":"25","author":"Ludwig","year":"2020","journal-title":"Oncologist"},{"issue":"21","key":"10.1016\/j.clml.2024.03.005_bib0002","doi-asserted-by":"crossref","first-page":"15674","DOI":"10.3390\/ijms242115674","article-title":"Immunotherapy of multiple myeloma: current status as prologue to the future","volume":"24","author":"Abramson","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"27","key":"10.1016\/j.clml.2024.03.005_bib0003","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.03.005_bib0004","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2024.03.005_bib0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clml.2024.03.005_bib0006","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2024.03.005_bib0007","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2024.03.005_bib0008","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"19","key":"10.1016\/j.clml.2024.03.005_bib0009","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2024.03.005_bib0010","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy","volume":"4","author":"Garfall","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"10.1016\/j.clml.2024.03.005_bib0011","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2024.03.005_bib0012","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.03.005_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-02826-w","article-title":"T-cell lymphoma and secondary primary malignancy risk after commercial CAR T-cell therapy","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2024.03.005_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2023.11846","article-title":"Fair allocation of scarce CAR T-cell therapies for relapsed\/refractory multiple myeloma","author":"Derman","year":"2023","journal-title":"JAMA"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.03.005_bib0015","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood-2022-162295","article-title":"Phase I open-label single-arm study of BCMA\/CD19 dual-targeting FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma","volume":"140","author":"Du","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.03.005_bib0016","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1182\/blood-2022-162615","article-title":"KarMMa-2 cohort 2c: efficacy and safety of idecabtagene vicleucel in patients with clinical high-risk multiple myeloma due to inadequate response to frontline autologous stem cell transplantation","volume":"140","author":"Dhodapkar","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.03.005_bib0017","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a phase1b, multicohort study","volume":"140","author":"Searle","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.03.005_bib0018","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.clml.2024.03.005_bib0019","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2024.03.005_bib0020","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.clml.2024.03.005_bib0021","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2024.03.005_bib0022","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10297","key":"10.1016\/j.clml.2024.03.005_bib0023","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2024.03.005_bib0024","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.clml.2024.03.005_bib0025","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.clml.2024.03.005_bib0026","article-title":"S197: LINKER-MM1 study: LINVOSELTAMAB (REGN5458) in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Lee","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.03.005_bib0027","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.03.005_bib0028","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.03.005_bib0029","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/17474086.2021.1962279","article-title":"Investigation of demographic features, performance, comorbidity status and mortality causes among multiple myeloma patients: real-life data","volume":"14","author":"\u015eahin","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2024.03.005_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.05.014","article-title":"Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies","volume":"189","author":"Rubinstein","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clml.2024.03.005_bib0031","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/10428194.2021.1992761","article-title":"Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies","volume":"63","author":"Jolles","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2024.03.005_bib0032","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12879-023-08070-w","article-title":"Mutations in immunodeficiency-related genes may increase the risk of infection after CAR-T-cell therapy: a report of two cases","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Infect Dis"},{"issue":"10","key":"10.1016\/j.clml.2024.03.005_bib0033","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.22.02197","article-title":"Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma","volume":"41","author":"Cliff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.03.005_bib0034","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40265-022-01697-0","article-title":"BCMA-targeted biologic therapies: the next standard of care in multiple myeloma therapy","volume":"82","author":"Paul","year":"2022","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.clml.2024.03.005_bib0035","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","article-title":"B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma","volume":"19","author":"Tai","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.clml.2024.03.005_bib0036","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","article-title":"Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis","volume":"7","author":"Chai","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2024.03.005_bib0037","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"5","key":"10.1016\/j.clml.2024.03.005_bib0038","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2024.03.005_bib0039","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.clml.2024.03.005_bib0040","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.2021014611","article-title":"T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?","volume":"139","author":"Moreau","year":"2022","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2024.03.005_bib0041","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1080\/10428194.2022.2113532","article-title":"T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape","volume":"63","author":"Kazandjian","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.03.005_bib0042","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.283590","article-title":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","author":"Hammons","year":"2023","journal-title":"Haematologica"},{"issue":"10396","key":"10.1016\/j.clml.2024.03.005_bib0043","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1016\/j.clml.2024.03.005_bib0044","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/01.HS9.0000846344.56300.e1","article-title":"P866: correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed\/refractory multiple myeloma patients treated with idecabtagene vicleucel (BB2121)","volume":"6","author":"Rytlewski","year":"2022","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.clml.2024.03.005_bib0045","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.03.005_bib0046","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.clml.2024.03.005_bib0047","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific t-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.03.005_bib0048","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2024.03.005_bib0049","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T13:03:12Z","timestamp":1716987792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2152265024001125"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.03.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}